OBJECTIVES: Bicuspid aortic valve (BAV) is the most prevalent congenital cardiac malformation, frequently associated with aortic dilatation (AD). The molecular mechanisms involved in AD and its aetiological link with BAV formation are poorly understood. Altered fibrillin-1 (FBN1) and metalloprotease-2, -9 (MMP2,9) protein activities have been suggested to be involved in BAV aortopathy. In addition, FBN2 participates in embryonic valve formation, but its possible involvement in BAV-associated AD has never been explored. In this report, we evaluate the expression levels of MMP2,9 and FBN1,2 in the ascending aorta of patients with normal or dilated aortas and with tricuspid aortic valve (TAV) or BAV, using appropriate tissue-specific reference genes.
INTRODUCTION
Bicuspid aortic valve (BAV) is the most common human congenital cardiac malformation, with an incidence of 1-2% in the population worldwide [1] . Approximately 50% of affected individuals develop bicuspid aortopathy, i.e. dilatation of any segment of the proximal aorta from the aortic root to the aortic arch [1] [2] [3] . Patients with bicuspid aortopathy are at risk of dissection and rupture of the artery with fatal consequences [1] [2] [3] .
The development of bicuspid aortopathy is attributed to genetic and haemodynamic factors. The most widely accepted hypothesis proposes that patients with BAV present structural defects of the aortic media that predispose to the dilatation of the artery under altered haemodynamic conditions generated by the abnormal valve morphology [2] [3] [4] . Although there is strong evidence for the contribution of both genetic and environmental factors to the disease aetiology, the connection between BAV embryology and the development of structural defects of the aortic wall is still missing.
Several lines of evidence have led to the hypothesis that bicuspid aortopathy initiates with a defective processing of fibrillin 1 (FBN1), causing detachment of vascular smooth-muscle cells from the extracellular matrix and release of matrix metalloproteinases (MMPs), which leads to lamellar fragmentation and disruption of the media layer [3] . This hypothesis is supported by studies indicating that affected patients show defective FBN1 and MMP (specially MMP2,9) activities in the media of the dilated aorta [1, [3] [4] [5] . However, it is not known whether the defective protein activity is the result of altered gene expression, protein processing or inhibition. In addition, although the involvement of FBN1 in BAV and Marfan-associated aortic dilatation (AD) has been extensively discussed, the possible involvement of FBN2 in non-syndromic AD has not been investigated. FBN2 is an interesting molecule in the context of BAV aortopathy because it is involved in both aortic valve embryonic development and aortic media histomorphology [6] [7] [8] . On this basis, we aimed to compare the expression levels of FBN1,2 and MMP2,9 in the dilated or normal ascending aorta of patients with BAV or normal, tricuspid aortic valve (TAV).
Real-time quantitative polymerase chain reaction (RT-qPCR) is the gold standard method to compare gene expression levels between different sample populations. Normalization with reference or housekeeping genes is used to enable the comparison of mRNA concentration across different samples [9, 10] . Several common reference genes are routinely used for normalization in most qPCR analyses but too frequently without further validation, despite numerous reports have found these classical reference genes inadequate for analysing gene expression in different tissues [10] , including the aorta [11] , under certain physiological conditions. Moreover, during the last decade, numerous studies dedicated to identify differentially expressed genes in the aneurysmatic aorta of patients with BAV or TAV did not validate the reference genes required for proper normalization of transcript concentration [12] [13] [14] [15] [16] [17] [18] . Nevertheless, even though a particular reference gene is validated for normalization of gene expression in a particular human tissue, its expression may result unstable when using a different cohort of patients [19] .
In a previous study, we identified three reference genes, CDKN1b, POLR2A and CASC3, which showed a high expression stability in a population of 52 patients with normal or dilated aortas and different morphologies of the aortic valve [19] . In this study, we report the expression of FBN1, FBN2, MMP2 and MMP9 in aortas of the same patient population using the aforementioned validated reference genes.
METHODS

Study population
Tissue samples from human ascending aorta were collected from a total of 52 patients subjected to surgical aortic valve repair or replacement, Yacoub or David procedures or coronary surgery at the 'Virgen de la Victoria Hospital' (M alaga, Spain). Patients were collected consecutively if they did not refuse their participation and technical problems did not exist. The standard preoperative clinical evaluation included transthoracic echocardiography in the left parasternal long and short axes. The diagnosis of BAV was based on imaging of the aortic valve demonstrating partial or total fusion of the commissures, with or without raphe and a fish-mouth appearance during systole [20] . The ascending aorta was assessed according to Roman et al. [21] and the thoracic aorta guidelines [22] . The aorta was considered to be dilated when the indexed tubular diameter was >2.1 cm/m 2 , measured inner edge to inner edge during end diastole.
The exclusion criteria included the following: complex congenital cardiopathies, syndromes, endocarditis and/or plaques of atheroma in the aorta and aortic valve morphology not clearly defined by echocardiography or surgery. The study followed the principles established in the Declaration of Helsinki. Written informed consent was obtained from all patients. Experimental procedures were approved by the Ethics and Research Committee of M alaga according to the Committee's guidelines for Human Tissue Research (M alaga, Spain).
Subjects for this study were divided into four groups depending on the aortic valve morphology and the aorta diameter as follows: 30 patients with TAV and normal aorta (NDTAV); 10 patients with TAV and dilated aorta (DTAV); 4 patients with BAV and normal aorta (NDBAV) and 8 patients with BAV and dilatation aorta (DBAV). Furthermore, we also analysed the effect of valve morphology, independently of aortic dilatation (TAV versus BAV) on gene expression, the effect of dilatation, independently of valve morphology (ND versus D) on gene expression and the correlation between aortic diameter and gene expression levels.
Tissue sample collection and RNA isolation
Tissue samples from the lateral or anterior wall of the ascending aorta, a few centimetres above the sinutubular junction were collected at the operating room, immediately immersed in liquid nitrogen and stored at -80 C until RNA extraction. Each sample was homogenized using IKA ultra-turrax T10B basic homogenizer (LABOTAQ, Spain). Total RNA was extracted using the mirVana Paris Kit (Ambion, Germany) following the manufacturer's instructions and treated with DNase I (Quiagen, Germany) to eliminate any trace of genomic DNA. RNA concentration and purity were evaluated with a Nanodrop D-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). Only samples with an OD260/280 ratio from 1.8 to 2.1 were selected for determination of mRNA expression by RT-qPCR. In addition, RNA integrity was confirmed by 1.2% denaturing formaldehyde agarose gel electrophoresis (data not shown).
cDNA synthesis RNA samples were reverse transcribed to cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, CA, USA) according to the manufacturer's recommendations. The reverse transcriptase reaction was performed with 100 ng RNA in a final volume of 20 ml. The thermocycler conditions consisted of a first step at 25 C for 10 min, followed by a second step at 37 C for 120 min. Then, samples were heated at 85 C for 5 min and cooled to 4 C. The cDNA was stored at -20 C until further analysis.
Real-time quantitative polymerase chain reaction
The RT-PCR was performed using an ABI PRISM 7500 FastRealTime PCR Instrument (Applied Biosystems, CA, USA). The total reaction volume was 20 ml, containing 10 ml of Taqman Gene Expression Master Mix (Applied Biosystems, CA, USA), 10 ng of cDNA per reaction and a concentration of 300 nM for both forward and reverse primers. The cycling conditions were two holding stages, the first at 50 C for 20 s and the second at 95 C for 10 min, followed by 40 cycles at 95 C for 15 s and at 60 C for 1 min. The efficiency amplification (E) and correlation coefficient (R 2 ) were calculated using the LingRegPCR software. The mRNA expression of target genes was normalized against one reference gene (CDKN1b) or against three reference genes (CDKN1b, POLR2A and CASC3). These were found to be most stable reference genes in this particular patient population, determined by the statistical algorithms GeNorm, NormFinder and Bestkeeper [19] . The delta-Ct method was used for normalization and quantification of expression values. The information about the specific Taqman assays (primers and hydrolysis probe) used for amplification is listed in Table 2 .
Statistical analysis
Comparisons of qualitative demographic and clinical characteristics were performed using the v 2 test. Comparisons of 
RESULTS
Patients
The demographic and clinical characteristics of the individuals included in the study are summarized in Table 1 . We found no significant differences in the demographic parameters except for the age between NDTAV and NDBAV (P = 0.032). Regarding the clinical parameters, we found significant differences in aortic insufficiency (P = 0.005) and in coronary disease (P = 0.001) between NDTAV and DTAV.
Gene expression in ascending aorta Figure 1 shows the expression levels of MMP2, MMP9, FBN1 and FBN2 in TAV versus BAV patients normalized against CDKN1b (Figs. 1A,B) or against CDKN1b, POLR2A and CASC3 (Figs. 1C,D) .
We found a significant increase of FBN2 expression in patients with BAV compared with patients with TAV, when expression data were normalized against one reference gene (P = 0.015) or against three reference genes (P = 0.019). Moreover, BAV patients also showed an increased FBN1 expression compared with TAV individuals, although it did not reach statistical significance. When the expression levels were compared between patients with a normal aorta and patients with a dilated aorta (Fig. 2) , no significant differences were obtained for any of the genes analysed. Figure 3 shows the expression levels of the four experimental genes in the aorta of NDTAV, DTAV, NDBAV and DBAV patients normalized against CDKN1b (Fig. 3A) or against CDKN1b, POLR2A and CASC3 (Fig. 3B) . Again, the expression levels of FBN2 were significantly increased (P = 0.040) in DBAV compared with DTAV individuals using one gene for normalization (Fig. 3A) . When using three genes for normalization (Fig. 3B) , a similar 2-fold increase was obtained but without reaching statistical significance. Although not significant, the difference in FBN1 and FBN2 expression between NDTAV and NDBAV patients showed a similar tendency when using one (Fig. 3A) or three genes (Fig. 3B) . No statistical differences were found in the expression levels of MMPs.
To inspect the relationship between FBN1 and FBN2 expression in the aorta of patients with defective valve and/or ascending aorta, we calculated and compared the ratio of expression of these two genes in the aorta of each patient (FBN1/FBN2; Fig. 4) . The ratio FBN1/FBN2 was higher in patients with TAV (Figs. 4A,C) and with normal aorta (Figs. 4B,C) , though these differences did not reach statistical significance.
The correlation analysis showed no linear relationship between aortic diameter and the expression levels of any of the four genes analysed (FBN1, FBN2, MMP2 and MMP9) normalized against one or three reference genes. Linear coefficients ranged between -0.01 and -0.02, with P-values ranging from 0.180 and 0.970.
DISCUSSION
In the population studied, patients with BAV had increased expression levels of FBN, especially FBN2, in the wall of the ascending aorta, irrespective of dilatation. The concentration of FBN2 transcripts was significantly higher in patients with BAV compared with patients with TAV, using one (Fig. 1A) and three (Fig. 1D) previously validated genes for normalization. FBN1 expression was also increased in patients with BAV, though significant differences were not reached. When four groups of patients were compared, similar differences between TAV and BAV patients were obtained (Fig. 3 , TAVND versus BAVND and TAVAD versus BAVAD), though significance was lost in some cases, probably due to the small number of individuals included. In addition, the ratio of expression FBN1/FBN2 was higher in BAV patients and in patients with AD (Fig. 4 ), but these differences did not reach statistical significance for any of the groups analysed. The correlation analyses revealed no significant linear relationship between gene expression levels and aortic diameter, confirming that differences in gene expression were not associated with AD. In conclusion, our data indicate that FBN transcription, especially FBN2, is increased in the ascending aorta of patients with BAV irrespective of dilatation, pointing to the involvement of this molecule in the development of BAV-associated AD.
To our knowledge, this is the first time that FBN2 is suggested to be involved in BAV disease. Although loss of FBN1 protein has been hypothesized to be an early trigger of AD associated with BAV [1, 4] , the possible involvement of FBN2 has never been addressed. FBN1 and 2 proteins have partially overlapping functions in vascular matrix microfibril formation [6] . FBN1 is the main microfibril component in adults, whereas FBN2 is mainly expressed during the embryonic and postnatal life, but the precise involvement of the later in the adult matrix is poorly understood. Interestingly, FBN2 null mice show shorter bones with syndactyly rather than longer bones found in FBN1 null mice [23] . In addition to their function in microfibril formation, FBN1 and FBN2 are able to modulate differentially the activity of TGFb and BMP signals, respectively, thus regulating vascular matrix homeostasis [6] . We hypothesize that an increased expression of FBN2 in the aorta of BAV patients might alter the microfibril structure, causing a defect in elastin deposition [6] , or might alter BMP signalling, affecting tissue homeostasis [24] . Alternatively, increased levels of FBN2 in the vascular wall might be the consequence, rather than the cause of the aortic media defect associated with BAV. The study of the molecular pathways associated with FBN2 expression in the aortic media may help to solve this issue.
Currently, it is widely accepted that the association between BAV and AD is the consequence of a common aetiology [2] [3] [4] . However, the connection between BAV embryology and the development of structural defects of the aortic wall is still missing. During embryonic development, in addition to its function in building elastic microfibrils, FBN2 is involved in the process of endocardial-tomesenchymal transformation, responsible for the formation of endocardial cushions of the embryonic heart [7, 8] . Several reports indicate that BAV formation results from anomalies in the formation of endocardial cushions or in the septation of the embryonic outflow tract, where endocardial cushions are also involved [25, 26]. These data allow speculating on the aetiological link between BAV formation in embryos and aneurysm development in adults. Abnormal (increased) FBN2 expression during cardiac outflow tract embryonic development might alter the formation of endocardial cushions, leading to BAV formation, whereas in the adult, excessive FBN2 deposition in aortic extracellular matrix might influence the development of AD. Although we do not have functional or embryonic data to sustain this statement, the fact that FBN2 specifically affects both valve formation and aortic histoarchitecture [6] [7] [8] is suggestive enough to raise this hypothesis.
The MMPs are a family of proteases that play a significant role in the homeostasis of connective tissue. MMP-1, -2 and -9 have been suggested to be involved in the development of ADs, as their protein activities are increased in aneurysmatic aortas of BAV compared with TAV patients [5] . However, some studies have shown no differences in MMPs gene expression levels in the normal or dilated aortas of BAV and TAV patients [27] . Our data agree with these studies in showing no statistically significant difference or tendency in the expression of MMP-2 and -9 in the different groups compared (Figs. 1-3 ). MMPs are regulated at different levels, including the inhibition of their activity by tissue inhibitors of metalloproteinases (TIMPs) [28] . Possibly, the increased MMP activity detected in the ascending aorta of patients with BAV [5] is caused by an altered MMP/TIMP ratio [27] instead of an increased of MMP transcription.
This study has several limitations, including the use of transthoracic echocardiography instead of magnetic resonance and computed tomography imaging and the slightly different location of the samples in the ascending aorta. However, the principal limitation is the limited sample size. This hinders the analysis of subgroups according to valve function, hides possible significant differences in the clinical variables examined and diminishes the significance of some statistical tests. Nevertheless, the quantification of RNA expression in aortas was performed using housekeeping genes previously validated for this particular patient population [19] . This confers a high degree of standardization on the experimental design, what is seldom reached in studies of this kind. Most studies designed to identify differentially expressed genes in the dilated aorta of patients with BAV did not validate the reference genes required for proper normalization [12] [13] [14] [15] [16] [17] [18] . It is well recognized that the stability of the reference genes must be demonstrated for the tissue and the cohort studied before any reliable data can be obtained [9] . Thus, although the use of the same cohort of patients as our previous study implies a relatively small patient population, we believe that the standardization of the reference genes assures a high degree of consistency of the results. In this regard, it should be noted that, although the number of samples is relatively small when comparing four groups of patients, this number rises to quite acceptable levels when two groups [TAV (n = 40) versus BAV (n = 12) or D (n =18) versus ND (n = 34)] are used. In any case, because we describe a single cohort, we consider the results to be hypothesis generating.
In conclusion, this study offers preliminary but consistent new results of the expression of FBNs and MMPs in the ascending aorta of patients with BAV and/or AD. Our data indicate that FBN2 transcription is increased in the ascending aorta of patients with BAV, uncovering a new possible molecular player in the development of BAV disease. In addition, the reported increase in MMP activity associated with AD does not seem to result from increased MMP transcription.
